

HETEROCYCLES, Vol. 71, No. 4, 2007, pp. 941 - 947. © The Japan Institute of Heterocyclic Chemistry
Received, 11th January, 2007, Accepted, 22nd February, 2007, Published online, 23rd February, 2007. COM-07-10999

FOUR NEW LIGNANS FROM *KADSURA HETEROCLITA*

Li-jia Xu,^a Yong Peng,^a Si-bao Chen,^{*b} Shi-lin Chen,^{a,b} and Pei-gen Xiao^{*a}

^aInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100094, P. R. China ^bState Key Laboratory of Chinese Medicine and Molecular Pharmacology, Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, P. R. China

Tel:+86-10-63011294, Fax:+86-10-63038753, E-mail: xiaopg@public.bta.net.cn

and bcsbchen@inet.polyu.edu.hk

Abstract- Four new lignans, heteroclitins I-L (**1-4**), were isolated from the stems of *Kadsura heteroclita* (Roxb.) Craib. Their chemical structures were elucidated on the basis of 1D and 2D NMR.

INTRODUCTION

Kadsura heteroclita (Roxb.) Craib (Schisandraceae), a climbing vine plant mainly distributed in the southwestern part of China, has been widely used in folk medicine for a long history to treat rheumatism and tracheitis.^{1,2} Its stems have been proved to possess biological activities to promote vital energy and blood circulation, to expel wind-evil and to remove wetness-evil. Previous phytochemical investigation revealed that this plant mainly contained lignans^{3,4} and triterpenoids.⁵⁻⁷ In the course of our exploration for natural products from Schisandra plants, we investigated the ether extract of the stems of *K. heteroclita*. In this report we describe the isolation and characterization of four new lignans, Heteroclitin I (**1**), Heteroclitin J (**2**), Heteroclitin K (**3**), Heteroclitin L (**4**).




Figure 1. Structures of 1-4

RESULTS AND DISCUSSION

Heteroclitin I (**1**), obtained as pale yellow needles, possessed molecular formula $C_{34}H_{34}O_{11}$ as determined by HREIMS (m/z 618.2107). The characteristic AB quartet signal at δ 4.61, 4.01 in the 1H NMR spectrum and a quaternary carbon at δ 63.09 in the ^{13}C NMR spectrum suggested that **1** possessed a spirobenzofuranoid skeleton.⁸ The CD and NMR spectra of **1** were similar to those of Kadsulignan D,⁹ suggesting a close analogue. The 1H NMR spectrum revealed the presence of one methyl singlet (δ 1.29, 3H s) and one secondary methyl group (δ 1.36, 3H d, $J=7.2$ Hz), assigned to CH_3 -18 and CH_3 -17, respectively; two aromatic protons (δ 6.55, 1H s; δ 6.56, 1H s); one methylenedioxy moiety (δ 5.97, 5.92 1H each, brs-like) and two methoxyl groups (δ 3.71, 3H s; δ 4.05, 3H s), located in the biphenyl rings. Moreover, the signals of a benzoate moiety (δ 7.34, 2H, d, $J=7.2$; δ 7.32, 2H, t, $J=8$; δ 7.54, 1H, t, $J=7.2$) and an angelate group (δ 1.75, 3H, s; δ 1.87, 3H, dd, $J=7.2$ Hz, δ 6.01, 1H, q, $J=7.2$ Hz) were observed in the NMR spectrum. Base on the mass spectrum, the two intense peaks at m/z 518 [$M^+-C_4H_7COOH$] and m/z 396 [$M^+-C_4H_7COOH-C_5H_6COOH$] are assigned to fragments produced by the 1, 2-elimination of benzoic acid and angelic acid *via* McLafferty ester rearrangement.¹⁰ The HMBC spectrum of **1** displayed the correlations between H-6 (δ 5.93, 1H s) with C-1' (δ_C 165.10) of the benzoyloxy group, and H-9 (δ 5.71, 1H s) with C-1'' (δ_C 165.84) of the angeloyloxy group, suggesting that the two ester groups were substituted at C-6 and C-9, respectively. According to the NOESY spectrum of **1**, the correlations between H-4 with H-6 α , and H-11 with H-9 β , indicated the benzoyloxy and angeloyloxy groups were located at 6 β and 9 α , respectively. Moreover, **1** bears a twist-boat-chair conformation^{11,12} according to the NOESY correlations of Me-18 with Me-17, H-9 β with Me-17, and Me-18 with H-6 α (Figure 2). From the

above data, **1** should possess a similar chemical structure as Kadsulignan D except for a benzoyloxy at C-6 instead of an angeloyloxy in Kadsulignan D.




Figure 2. Key NOE correlations of **1**.

Heteroclitin J (**2**) and K (**3**) have the molecular formula $C_{31}H_{30}O_{11}$ and $C_{36}H_{32}O_{11}$, corresponding to the molecular ion peak at m/z 578.1777 and m/z 640.1945 in the HREIMS, respectively. Their IR, UV, CD and NMR spectra were similar to those of **1**, which indicated **2** and **3** were analogues of **1**. The NMR spectra demonstrated the presence of one secondary methyl, one tertiary methyl, one methylenedioxy, two methoxys and two aromatic protons in **2** and **3**. In addition, signals of one acetyl and one benzoyl group in **2** and two benzoyl groups in **3** were observed. The presence of these substituents is also in agreement with the EI-MS fragment peaks at m/z 518 [$M^+ - CH_3COOH$] and m/z 396 [$M^+ - CH_3COOH - C_5H_6COOH$] in **2** and fragment peaks at m/z 518 [$M^+ - C_5H_6COOH$] and m/z 396 [$M^+ - C_5H_6COOH - C_5H_6COOH$] in **3**. The HMBC spectrum of **2** revealed that the carbonyl carbon (δ 165.09) of the benzoyloxy has correlation to H-6 (δ 5.90, 1H, s), while the carbonyl carbon (δ 168.62) of acetyloxy group correlated to H-9 (δ 5.89, 1H, s). Thus, the location of the benzoyloxy group is at C-6 and that of the acetyloxy group at C-9. Based on the NOESY spectrum, the configuration of **2** and **3** was determined to be the same as that of **1**. So, the structure of **2** and **3** were defined as those shown in Figure 1.

Table 1 ^1H NMR(400 MHz, CDCl_3) Data for Compounds **1-4**

| | 1 | 2 | 3 | 4 |
|--------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| 4 | 6.55 (1H, s) | 6.52 (1H, s) | 6.56 (1H, s) | 6.53 (1H, s) |
| 11 | 6.56 (1H, s) | 6.51 (1H, s) | 6.64(1H, s) | 6.50 (1H, s) |
| 6 | 5.93 (1H, s) | 5.90 (1H, s) | 6.02 (1H,m) | 5.79 (1H, s) |
| 9 | 5.71 (1H, s) | 5.89 (1H, s) | 5.93 (1H, s) | 5.84 (1H, s) |
| 8 | 2.29 (1H,q, $J=7.2$) | 2.25 (1H,q, $J=7.2$) | 2.37 (1H,q, $J=7.2$) | 2.23 (1H,q, $J=7.2$) |
| 17 | 1.36 (3H, d, $J=7.2$) | 1.33 (3H, d, $J=7.2$) | 1.41 (3H, d, $J=7.2$) | 1.38 (3H, d, $J=7.2$) |
| 18 | 1.29 (3H, s) | 1.27 (3H, s) | 1.35 (3H, s) | 1.32 (3H, s) |
| 19 | 4.61, 4.01 (1H each, ABq, $J=8.8$) | 4.79, 4.06 (1H each, ABq, $J=8.8$) | 4.63, 4.02 (1H each, ABq, $J=8.8$) | 4.63, 4.02 (1H each, ABq, $J=8.8$) |
| 7-OH | 2.91 (brs) | 2.54 (brs) | 2.95 (brs) | 2.94 (brs) |
| 2-OCH ₃ | 3.71 (3H, s) | 3.77 (3H, s) | 3.16 (3H, s) | 3.14 (3H, s) |
| 3-OCH ₃ | 4.05 (3H, s) | 4.09 (3H, s) | 3.90 (3H, s) | 3.89 (3H, s) |
| OCH ₂ O | 5.97, 5.92 (1H each, brs-like) | 5.95, 5.91 (1H each, brs-like) | 5.99, 5.93 (1H each, brs-like) | 5.98, 5.93 (1H each, brs-like) |
| | Ang | Ac | Bz | Bz |
| | 3' 6.01 (1H, dd, $J=7.2$) | 2' 1.88 (3H, s) | 3',7' 7.72 (2H, d, $J=7.2$) | 3',7' 7.70 (2H, d, $J=7.2$) |
| | 4' 1.87 (3H,d, $J=7.2$) | | 4',6' 7.30 (2H, overlapped) | 4',6' 7.37 (2H, t, $J=8$) |
| | 5' 1.75 (3H, s) | | 5' 7.54 (1H, t, $J=7.2$) | 5' 7.54 (1H, t, $J=7.2$) |
| | Bz | Bz | Bz | Ang |
| | 3",7" 7.34 (2H, d, $J=7.2$) | 3",7" 7.34 (2H, d, $J=7.2$) | 3",7" 7.34 (2H, overlapped) | 3" 6.10 (1H, dd, $J=7.2$) |
| | 4",6" 7.32 (2H, t, $J=8$) | 4",6"7.30 (2H, t, $J=8$) | 4",6" 7.30 (2H, overlapped) | 4" 1.90 (3H,d, $J=7.2$) |
| | 5" 7.54 (1H, t, $J=7.2$) | 5" 7.53 (1H, t, $J=7.2$) | 5" 7.54 (1H, t, $J=7.2$) | 5" 1.35 (3H, s) |

Heteroclitin L (**4**) has the same molecular formula $\text{C}_{34}\text{H}_{34}\text{O}_{11}$ as that of **1** based on HREIMS (m/z 618.2119). The NMR signals also suggested that **4** had a similar structure as **1**. However, from the HMBC spectrum of **4**, the correlation between C-1' (δ 166.24) and H-6 (δ 5.79, 1H, s) clearly indicated that the angelic acid ester should be located at C-6. In addition, the correlation between C-1'' (δ 165.48) and H-9 (δ 5.84, 1H, s) revealed that the benzoic acid ester was located at C-9. Further NOESY experiments confirmed that **4** possessed 6 β -angeloyloxyl and 9 α -bezoyloxyl groups, like **1**, **2** and **3**.

The CD spectra of **1-4** showed negative Cotton effect around 320 nm and positive effect around 370 nm, which indicated that the spirobenzofuranoid skeleton has the same 16*S* configuration.⁸

EXPERIMENTAL

General Experimental Procedures. The CD spectra were recorded on a J-715 (JASCO) spectropolarimeter. Optical rotations were performed on a Perkin-Elmer digital polarimeter. Melting points were measured on a Fisher-Johns apparatus and were uncorrected.

Table 2 ^{13}C NMR(400 MHz, CDCl_3) Data for Compounds 1-4

| | 1 | 2 | 3 | 4 |
|-------------------|--------|--------------|--------------|--------------|
| 1 | 194.66 | 196.04 | 194.73 | 194.92 |
| 2 | 132.31 | 131.88 | 132.09 | 132.01 |
| 3 | 155.00 | 155.61 | 154.67 | 154.82 |
| 4 | 122.84 | 123.05 | 123.91 | 123.84 |
| 5 | 141.39 | 141.79 | 140.41 | 140.57 |
| 6 | 82.37 | 81.46 | 82.14 | 81.97 |
| 7 | 75.38 | 75.18 | 75.60 | 75.51 |
| 8 | 44.15 | 44.13 | 44.35 | 44.15 |
| 9 | 82.51 | 82.37 | 83.67 | 83.74 |
| 10 | 129.73 | 129.24 | 128.72 | 129.26 |
| 11 | 100.96 | 101.21 | 101.28 | 101.30 |
| 12 | 150.28 | 150.16 | 150.24 | 150.20 |
| 13 | 130.35 | 130.42 | 130.49 | 130.16 |
| 14 | 143.43 | 143.43 | 143.55 | 143.57 |
| 15 | 120.08 | 120.29 | 120.27 | 119.74 |
| 16 | 63.09 | 63.25 | 62.97 | 62.95 |
| 17 | 18.05 | 17.75 | 18.03 | 18.09 |
| 18 | 28.28 | 28.41 | 28.57 | 28.61 |
| 19 | 77.34 | 77.35 | 79.08 | 77.40 |
| 20 | 101.94 | 101.98 | 102.00 | 101.94 |
| 2- OCH_3 | 58.77 | 58.94 | 58.97 | 58.69 |
| 3 OCH_3 | 58.55 | 58.89 | 58.55 | 58.47 |
| | Ang | Ac | Bz | Bz |
| 1' | 165.84 | 1' 168.62 | 1' 165.06 | 1' 165.48 |
| 2' | 141.93 | 2' 20.35 | 2' 128.72 | 2' 128.67 |
| 3' | 124.68 | | 3',7' 129.43 | 3',7' 129.41 |
| 4' | 20.54 | | 4',6' 128.35 | 4',6' 128.37 |
| 5' | 15.95 | | 5' 133.30 | 5' 133.28 |
| | Bz | Bz | Bz | Ang |
| 1" | 165.10 | 1" 165.09 | 1" 165.52 | 1" 166.24 |
| 2" | 128.20 | 2" 128.31 | 2" 129.38 | 2" 142.17 |
| 3",7" | 129.77 | 3",7" 129.74 | 3",7" 129.78 | 3" 125.99 |
| 4",6" | 128.31 | 4",6" 128.17 | 4",6" 128.40 | 4" 19.25 |
| 5" | 133.86 | 5" 133.88 | 5" 133.91 | 5" 15.70 |

UV spectra were measured on Perkin-Elmer Lambda 35 UV/VIS spectrometer. NMR spectra were measured on a Bruker AV 400 spectrometer with TMS as an internal standard. EI-MS spectra were obtained using a Micromass ZabSpec high-resolution mass spectrometer. Silica gel and silica gel GF₂₅₄ sheets (both from Qingdao Haiyang Chemical Group Co., Qingdao, Shandong Province, People's Republic of China) were used for column chromatography and TLC, respectively.

Plant Material *Kadsura heteroclita* (Roxb.) Craib. (Schisandraceae) was collected at Sangzhi, Hunan Province, People's Republic of China, in November 2004, and identified by Prof.

Si-bao Chen, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College. A voucher specimen (2004KH09) has been deposited in the Herbarium of this institute.

Extraction and Isolation The dried stems of *Kadsura heteroclita* (Roxb.) Craib. (15 kg) were pulverized and extracted with 95% EtOH under reflux (2h×3). The ethanolic extract was concentrated under reduced

pressure and the concentrate mixed with 1kg of SiO₂. After evaporation of the solvent, the mixture was extracted with Et₂O in a Soxhlet apparatus. The ether extract (120g) was further separated by silica gel column chromatography by a gradient system of cyclohexane-acetone and purified repeatedly by silica gel and Sephadex LH-20 column to afford four lignans, Heteroclitin I (**1**, 968 mg), J (**2**, 8 mg), K (**3**, 92 mg) and L (**4**, 79 mg).

Heteroclitin I (1): Yellow needles, mp 192-194 °C; $[\alpha]_D^{20}$ -122.3° (*c* 1.09, MeOH); CD (MeOH) $\Delta\epsilon_{nm}$: +33.42 (220), -38.50 (322), + 38.95 (370); UV (MeOH) λ_{max} (log ϵ) 219 (4.75), 275 (sh, 3.35), 325 (3.41) nm; IR (KBr) ν_{max} 3575, 2912, 1712, 1658, 1581, 1454, 1269 cm⁻¹; ¹H and ¹³C NMR data (Table 1 and Table 2); EIMS *m/z* 618 [M]⁺, 518, 476, 447, 396, 353, 341, 325, 313, 105, 83; HREIMS *m/z* 618.2107 [M]⁺ (calcd for C₃₄H₃₄O₁₁, 618.2101).

Heteroclitin J (2): Yellow gum, $[\alpha]_D^{20}$ -60.5° (*c* 0.16, CH₃OH); CD (MeOH) $\Delta\epsilon_{nm}$: +34.60 (223), -57.95 (322), + 60.04 (370); UV (MeOH) λ_{max} (log ϵ) 220 (4.21), 281 (3.12), 326 (3.15) nm; IR (KBr) ν_{max} 3565, 2920, 1712, 1652, 1575, 1459, 1251cm⁻¹; ¹H and ¹³C NMR data (Table 1 and Table 2); EIMS *m/z* 578 [M]⁺, 518, 476, 447, 396, 353, 341, 325, 313, 105, 83; HREIMS *m/z* 578.1777 [M]⁺ (calcd for C₃₁H₃₀O₁₁, 578.1788).

Heteroclitin K (3): Yellow needles, mp 195-198 °C; $[\alpha]_D^{20}$ -161.7° (*c* 1.03, MeOH); CD (MeOH) $\Delta\epsilon_{nm}$: -44.00 (220), -25.91 (320), +19.47 (370); UV (MeOH) λ_{max} (log ϵ) 220(4.56), 280 (3.21), 325 (3.29) nm; IR (KBr) ν_{max} 3568, 2923, 1735, 1708, 1658, 1581, 1450, 1245 cm⁻¹; ¹H and ¹³C NMR data (Table 1 and Table 2); EIMS *m/z* 640 [M]⁺, 518, 476, 447, 396, 353, 341, 325, 313, 105, 83; HREIMS *m/z* 640.1952 [M]⁺ (calcd for C₃₆H₃₂O₁₁, 640.1945).

Heteroclitin L (4): Yellow needles, mp 128-130 °C; $[\alpha]_D^{20}$ -28.0° (*c* 0.98, MeOH); CD (MeOH) $\Delta\epsilon_{nm}$: +23.30 (222), -56.12 (320), +50.54 (370); UV (MeOH) λ_{max} (log ϵ) 221 (4.65), 278 (3.11), 327 (3.24) nm; IR (KBr) ν_{max} 3502, 2943, 1716, 1647, 1581, 1454, 1250cm⁻¹; ¹H and ¹³C NMR data (Table 1 and Table 2); EIMS *m/z* 618 [M]⁺, 496, 454, 425, 396, 353, 343, 325, 313, 105, 83; HREIMS *m/z* 618.2119 [M]⁺ (calcd for C₃₄H₃₄O₁₁, 618.2101).

ACKNOWLEDGEMENTS

The authors thank the *National Natural Science Foundation of Peoples Republic of China* for financial support (No. 30530860).

REFERENCES

1. D. F. Chen, G. J. Xu, X. W. Yang, M. Hattori, Y. Tezuka, T. Kikuchi, and T. Namba, *Phytochemistry*, 1992, **31**, 629.
2. X. W. Yang, M. Hattori, T. Namba, D. F. Chen, and G. J. Xu, *Chem. Pharm. Bull.*, 1992, **40**, 406.
3. G. Q. Han, P. Dai, R. Xue, B. H. Arison, D. C. Lankin, and S. B. Hwang, *J. Chinese Pharm. Sci.*, 1992, **1**, 20.
4. X. W. Yang, H. Miyashiro, M. Hattori, T. Namba, Y. Tezuka, T. Kikuchi, D. F. Chen, G. J. Xu, and T. Hori, *Chem. Pharm. Bull.*, 1992, **40**, 1510.
5. Y. P. Chen, Z. W. Lin, H. J. Zhang, and H. D. Sun, *Phytochemistry*, 1990, **29**, 3358.
6. L. N. Li, H. Xue, D. L. Ge, K. Kangouri, T. Miyoshi, and S. Omura, *Planta Medica*, 1989, **55**, 300.
7. K. Kangouri, T. Miyoshi, A. Kawashima, A. Ikeda, T. Mizutani, S. Omura, L. N. Li, and H. Xue, *Planta Medica*, 1989, **55**, 297.
8. L. N. Li and H. Xue, *Phytochemistry*, 1990, **29**, 2730.
9. J. S. Liu, M. F. Huang, and H. X. Zhou, *Can. J. Chem.*, 1991, **69**, 1403.
10. M. D. Wu, R. L. Huang, L. M. Kuo Yang, C. C. Hung, C. W. Ong, and Y. H. Kuo, *Chem. Pharm. Bull.*, 2003, **51**, 1233.
11. D. F. Chen, S. X. Zhang, K. Chen, B. N. Zhou, P. Wang, L. M. Cosentino, and K. H. Lee, *J. Nat. Prod.*, 1996, **59**, 1066.
12. Y. G. Chen, P. Wang, Z. W. Lin, H. D. Sun, G. W. Qin, and Y. Y. Xie, *Phytochemistry*, 1998, **48**, 1059.